Ipsen announced an immediate market withdrawal of tazemetostat (Tazverik) following detection of secondary hematologic malignancies in a confirmatory trial, the company said. The decision halts ongoing clinical studies and removes the drug from commercial availability while monitoring and patient care steps are enacted. Ipsen cited an independent data monitoring committee’s findings as the basis for the action. The withdrawal underscores post‑approval safety monitoring’s impact on commercial products and highlights risks inherent to accelerated approval pathways and confirmatory studies. Ipsen said the move will have limited near‑term financial impact but will prompt reassessment of development priorities and long‑term plans for the asset.